medicina51巻4号

2014年04月発行

特集 虚血性心疾患up to date―内科医によるトータルマネジメント 冠動脈疾患における多面的内科マネジメント

脂質管理・血糖管理―どこまで下げるか，いかに下げるか

著者： 矢作直也¹

所属機関： ¹筑波大学医学医療系内分泌代謝・糖尿病内科

ページ範囲：P.666 - P.674

ポイント

◎2012年改訂の動脈硬化性疾患予防ガイドラインから，絶対リスクが採用された．

◎血糖管理は早期からの開始が重要である．

参考文献

1）日本動脈硬化学会：動脈硬化性疾患予防ガイドライン2012年版

2）National Cholesterol Education Program：Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 148：36-69, 1988

3）National Cholesterol Education Program：Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults（Adult Treatment Panel Ⅱ）. Circulation 89：1333-1445, 1994

4）National Cholesterol Education Program（NCEP）Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults（Adult Treatment Panel Ⅲ）：Third Report of the National Cholesterol Education Program（NCEP）Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults（Adult Treatment Panel Ⅲ）final report. Circulation 106：3143-3421, 2002

5）Matsuzaki M, et al：Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 66：1087-1095, 2002

6）Hata Y, et al：Report of the Japan Atherosclerosis Society（JAS）Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults. J Atheroscler Thromb 9：1-27, 2002

7）NIPPON DATA80 Research Group：Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ J 70：1249-1255, 2006

8）Nakamura H, et al：Primary prevention of cardiovascular disease with pravastatin in Japan（MEGA Study）；A prospective randomised controlled trial. Lancet 368：1155-1163, 2006

9）Yokoyama M, et al：Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients（JELIS）；A randomised open-label, blinded endpoint analysis. Lancet 369：1090-1098, 2007

10）Teramoto T, et al：Executive summary of Japan Atherosclerosis Society（JAS）guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 14：45-50, 2007

11）Teramoto T, et al：Executive summary of the Japan Atherosclerosis Society（JAS）guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan-2012 version. J Atheroscler Thromb 20：517-523, 2013

12）Stone NJ, et al：2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults；A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2013 Nov 12.［Epub ahead of print］

13）The Diabetes Control and Complications Trial Research Group：The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329：977-986, 1993

14）Ohkubo Y, et al：Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus：a randomized prospective 6-year study. Diabetes Res Clin Pract 28：103-117, 1995

15）UK Prospective Diabetes Study（UKPDS）Group：Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes（UKPDS 33）. Lancet 352：837-853, 1998

16）日本糖尿病学会：科学的根拠に基づく糖尿病診療ガイドライン2013，2013

17）Gaede P, et al：Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348：383-393, 2003

18）Holman RR, et al：10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359：1577-1589, 2008

19）Nathan DM, et al：Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353：2643-2653, 2005

20）Scirica BM, et al：Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369：1317-1326, 2013

21）White WB, et al：Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369：1327-1335, 2013